New Hope for Sickle Cell Disease: Groundbreaking Gene Therapies Under Review

By Staff Writer

July 19, 2023

The Institute for Clinical and Economic Review (ICER) has released an updated Evidence Report assessing the potential impact of two revolutionary gene therapies for sickle cell disease (SCD) – exagamglogene autotemcel (exa-cel) and lovotibeglogene autotemcel (lovo-cel). 

Sickle cell disease is an inherited blood disorder caused by mutations in the gene HBB, affecting hundreds of thousands of people globally. The disease causes a range of severe health issues and is currently treated with supportive care, blood transfusions, and hydroxyurea. The only potentially curative treatment is hematopoietic stem cell transplantation (HSCT), but it carries significant risks. Two new gene therapies, lovo-cel and exa-cel, are emerging as potential treatments for SCD. Both have shown promising results in clinical trials, reducing the number of vaso-occlusive events or crises in patients. However, they also carry risks of serious adverse events and uncertainties about their long-term effects. The FDA has accepted the Biologics License Application for both therapies, with regulatory decisions expected in December 2023. The cost-effectiveness of these therapies will depend on their actual prices.

As the prices for lovo-cel and exa-cel are not available yet, and a placeholder value of $2 million was assumed based on analyst estimates. A sensitivity analysis was conducted to evaluate the effects of uncertainty on costs and health outcomes. The cost of VOCs, the utility of patients successfully treated with gene therapy, and the annual number of VOCs were found to be the major drivers of cost per QALY for both treatments. There was greater uncertainty around the treatment success rate of exa-cel due to a small sample size in the trial. The hazard ratios for death, acute, and chronic complications were estimated from published literature and varied based on the age of treatment.

The report indicates that lovo-cel may provide a substantial net health benefit for severe SCD patients, while exa-cel could offer comparable or possibly greater benefits. 

Several studies have been conducted on SCD in recent years, focusing on complications, costs, utilities, and conceptual modeling. These studies have been crucial in the development of a cost-effectiveness model and addressing uncertainties in modeling SCD. However, there are still uncertainties regarding the impact of SCD gene therapy on quality of life and disease-related events. The cost-effectiveness of gene therapies also depends on the patient’s age, with younger patients associated with a lower cost-effectiveness ratio. Some people living with SCD may not opt for gene therapies due to their preferences and risk-benefit tradeoffs. The cost-effectiveness model assumes risk neutrality, which is a limitation. The potential cost savings and health gains contribute to the justification for the cost of gene therapies.

ICER’s Chief Medical Officer, David Rind, MD, highlighted the potential of these therapies to address the underlying genetics of SCD, bringing us closer to a cure. However, he also emphasised the need for caution due to potential risks associated with autologous bone marrow transplantation and the uncertainties surrounding CRISPR therapy. 

Reference url

Recent Posts

Argentina WHO Withdrawal
   

Argentina WHO Withdrawal: President Milei Exits Global Health Alliance Amid COVID-19 Disputes

💡 *What happens when a country decides to withdraw from global health organizations?*
Argentina’s President Javier Milei has made the bold move to withdraw from the WHO, citing significant disagreements over health management during the pandemic. This decision raises questions about national sovereignty, cooperation, and the future of global health initiatives. Dive into the implications of Argentina’s stance and what it means for international health governance.

#SyenzaNews #globalhealth #healthcarepolicy

Gauteng HPV vaccination campaign
      

Gauteng HPV Vaccination Campaign: Protecting Girls Against Cervical Cancer

💉 Ready to protect our future generations from cervical cancer?

The Gauteng HPV vaccination campaign aims to vaccinate grade 5, 6, and 7 girls against the virus that causes most cervical cancers. By leveraging a single-dose regimen, this initiative not only enhances access to life-saving vaccines but also strives to meet ambitious global health targets.

Explore how this campaign is reshaping health outcomes in South Africa and why parental consent is key to its success.

#SyenzaNews #HealthEconomics #HealthcareInnovation #UniversalHealthCoverage

Capvaxive vaccine approval
     

Capvaxive Vaccine Approval

🌍 What if a single vaccine could significantly change the landscape of pneumococcal disease prevention in adults?

The European Medicines Agency has just recommended Merck’s Capvaxive, an innovative 21-valent pneumococcal conjugate vaccine! With robust data from multiple phase 3 trials, this potential approval marks a pivotal step in the fight against invasive Streptococcus pneumoniae infections in the EU. Look into how Capvaxive could enhance public health outcomes and offer extensive serotype coverage.

#SyenzaNews #pharmaceuticals #healthcarepolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.